Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AV-MEL-1

Latest Information Update: 07 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AiVita Biomedical
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 01 Jun 2019 Pooled efficacy data from phase II trials in Malignant melanoma (Late-stage disease) presented at the 55th American Society of Clinical Oncology (ASCO-2019)
  • 16 Jan 2019 The US FDA approves IND application for AV MEL 1 in Malignant melanoma (combination therapy)
  • 16 Nov 2018 Aivita Biomedical plans a phase I trial for Melanoma (Combination therapy, Metastatic disease, First-line therapy) in June 2019 (NCT03743298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top